A Phase 3 interventional study of Budesonide oral suspension in Eosinophilic Esophagitis (EoE), sponsored by Shire. Terminated at 45 sites in United States. Open to participants aged 11 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-02-19.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing budesonide in Eosinophilic Esophagitis — 1 open to participants now, 2 under way, 1 of them phase 3. Budesonide · Eosinophilic Esophagitis.
Among the 18 studies testing budesonide in Eosinophilic Esophagitis, this one is the 5th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 14th registered.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
Browse Eosinophilic Esophagitis studies →1 of the 18 studies testing budesonide in Eosinophilic Esophagitis is open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.
This study: 11 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 7 · Phase 4 3
First in 2005; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is above the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.
Median enrollment 79 across the 18 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 5 studies filed under Eosinophilic Esophagitis — fewer than ten, so there is no comparison to draw.
1 of the studies testing budesonide in Eosinophilic Esophagitis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596252Phase 3Dr. Falk Pharma GmbHOnce Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing budesonide in Eosinophilic Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study. The purpose of this study is to see if BOS is safe and well tolerated over the long-term in adolescents and adults with EoE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 10 milliliters (mL) of budesonide oral suspension at a concentration of 0.2 milligram per milliliter (mg/mL), twice daily, for up to 4 years 5 months.
Drug: Budesonide oral suspension
BOS 10 mL twice daily.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, and is an important medical event. Both serious and Non-serious TEAEs were reported in this outcome measure. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose.
Time frame: From start of study drug administration up to End of study (EOS) (Up to Month 53)
Number of Participants With Clinically Significant Physical Examination Findings
Number of participants with clinically significant physical examination findings were reported. Clinical significance was determined by investigator.
Time frame: From start of study drug administration up to EOS (Up to Month 53)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Participants were assessed by investigator for any clinically significant changes in vital parameters like temperature, systolic and diastolic blood pressure, pulse, respiratory rate, BMI, and weight. Vital signs were assessed after the participant had been in a supine position for at least 5 minutes immediately prior to the assessment. The criteria for clinically significant change was as per the investigators discretion.
Time frame: From start of study drug administration up to EOS (Up to Month 53)
Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Month 12
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is less than (\<) -2, suggesting a worse outcome (i.e., osteoporosis). Change from baseline in BMD for adolescents assessed by DXA Scan at Month 12 was reported.
Time frame: Baseline, Month 12
Change From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 24
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \<-2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 24 was reported.
Time frame: Baseline, Month 24
Change From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 36
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 36 was reported.
Time frame: Baseline, Month 36
Change From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 48
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 48 was reported.
Time frame: Baseline, Month 48
Change From Baseline in BMD For Adolescents Assessed by DXA Scan at EOS (Up to Month 53)
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at EOS (up to Month 53) was reported.
Time frame: Baseline, EOS (Up to Month 53)
Change From Baseline in Cortisol Level After Adrenocorticotropic Hormone (ACTH) Stimulation at Month 12
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 12 and reported in this outcome measure.
Time frame: Baseline, Month 12
Change From Baseline in Cortisol Level After ACTH Stimulation at Month 24
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 24 and reported in this outcome measure.
Time frame: Baseline, Month 24
Change From Baseline in Cortisol Level After ACTH Stimulation at Month 36
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 36 and reported in this outcome measure.
Time frame: Baseline, Month 36
Change From Baseline in Cortisol Level After ACTH Stimulation at Month 48
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 48 and reported in this outcome measure.
Time frame: Baseline, Month 48
Change From Baseline in Cortisol Level After ACTH Stimulation at EOS (Up to Month 53)
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at EOS (up to Month 53) and reported in this outcome measure.
Time frame: Baseline, EOS (Up to Month 53)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
Clinical laboratory parameters included hematology, chemistry, urinalysis; urine pregnancy test. Number of participants with potential clinically significant changes in laboratory parameters which were deemed clinically meaningful by the investigator were reported.
Time frame: From start of study drug administration up to EOS (Up to Month 53)
This study was conducted at 44 active sites in North America from 05 October 2017 (first participant enrolled) to 26 April 2022 (last participant completed).
| Milestone | BOS-BOS | PBO-BOS |
|---|---|---|
| Started | 122 | 11 |
| Treated | 121 | 10 |
| Completed | 0 | 0 |
| Not completed | 122 | 11 |
| Withdrew: Adverse event | 6 | 0 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Withdrawal by subject | 31 | 1 |
| Withdrew: Withdrawal by parent/guardian | 2 | 0 |
| Withdrew: Physician decision | 4 | 1 |
| Withdrew: Study terminated by sponsor | 56 | 6 |
| Withdrew: Site terminated by sponsor | 4 | 0 |
| Withdrew: Lost to follow-up | 12 | 2 |
| Withdrew: Pregnancy | 2 | 0 |
| Withdrew: Non-compliance with study drug | 2 | 0 |
| Withdrew: Not treated | 1 | 1 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, and is an important medical event. Both serious and Non-serious TEAEs were reported in this outcome measure. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose.
| Participants | BOS-BOS | PBO-BOS |
|---|---|---|
| TEAEs | 93 | 7 |
| Serious TEAEs | 11 | 0 |
Number of participants with clinically significant physical examination findings were reported. Clinical significance was determined by investigator.
| Participants | BOS-BOS | PBO-BOS |
|---|---|---|
| Moon Face | 0 | 0 |
| Acne | 2 | 0 |
| Hirsutism | 0 | 0 |
| Mood swings | 0 | 0 |
| Insomnia | 0 | 0 |
| Depression | 1 | 0 |
Participants were assessed by investigator for any clinically significant changes in vital parameters like temperature, systolic and diastolic blood pressure, pulse, respiratory rate, BMI, and weight. Vital signs were assessed after the participant had been in a supine position for at least 5 minutes immediately prior to the assessment. The criteria for clinically significant change was as per the investigators discretion.
| Participants | BOS-BOS | PBO-BOS |
|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 |
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is less than (\<) -2, suggesting a worse outcome (i.e., osteoporosis). Change from baseline in BMD for adolescents assessed by DXA Scan at Month 12 was reported.
| Z-score | BOS-BOS |
|---|---|
| Baseline Lumbar Spine (L1- L4) | -0.525 ± 1.0583 |
| Change at Month 12 Lumbar Spine (L1- L4) | 0.315 ± 0.3618 |
| Baseline Whole Body | -0.565 ± 0.9464 |
| Change at Month 12 Whole Body | 0.250 ± 0.2599 |
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \<-2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 24 was reported.
| Z-score | BOS-BOS |
|---|---|
| Baseline Lumbar Spine (L1- L4) | -0.525 ± 1.0583 |
| Change at Month 24 Lumbar Spine (L1- L4) | 0.445 ± 0.7312 |
| Baseline Whole Body | -0.565 ± 0.9464 |
| Change at Month 24 Whole Body | 0.092 ± 0.5326 |
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 36 was reported.
| Z-score | BOS-BOS |
|---|---|
| Baseline Lumbar Spine (L1- L4) | -0.525 ± 1.0583 |
| Change at Month 36 Lumbar Spine (L1- L4) | 0.603 ± 0.9089 |
| Baseline Whole Body | -0.565 ± 0.9464 |
| Change at Month 36 Whole Body | 0.870 ± 0.6447 |
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 48 was reported.
| Z-score | BOS-BOS |
|---|---|
| Baseline Lumbar Spine (L1- L4) | -0.525 ± 1.0583 |
| Change at Month 48 Lumbar Spine (L1- L4) | 0.657 ± 0.4813 |
| Baseline Whole Body | -0.565 ± 0.9464 |
| Change at Month 48 Whole Body | 0.817 ± 0.4521 |
The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at EOS (up to Month 53) was reported.
| Z-score | BOS-BOS |
|---|---|
| Baseline Lumbar Spine (L1- L4) | -0.525 ± 1.0583 |
| Change at EOS (Up to Month 53) Lumbar Spine (L1- L4) | 0.482 ± 0.6539 |
| Baseline Whole Body | -0.565 ± 0.9464 |
| Change at EOS (Up to Month 53) Whole Body | 0.350 ± 0.7541 |
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 12 and reported in this outcome measure.
| micrograms per deciliter (mcg/dL) | BOS-BOS | PBO-BOS |
|---|---|---|
| Baseline | 10.49 ± 5.508 | 13.15 ± 7.188 |
| Change At Month 12 | 0.06 ± 6.215 | 6.77 ± 8.835 |
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 24 and reported in this outcome measure.
| mcg/dL | BOS-BOS | PBO-BOS |
|---|---|---|
| Baseline | 10.49 ± 5.508 | 13.15 ± 7.188 |
| Change At Month 24 | 0.81 ± 6.127 | -2.58 ± 3.727 |
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 36 and reported in this outcome measure.
| mcg/dL | BOS-BOS | PBO-BOS |
|---|---|---|
| Baseline | 10.49 ± 5.508 | 13.15 ± 7.188 |
| Change At Month 36 | 0.70 ± 5.773 | -1.63 ± 3.845 |
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 48 and reported in this outcome measure.
| mcg/dL | BOS-BOS | PBO-BOS |
|---|---|---|
| Baseline | 10.49 ± 5.508 | 13.15 ± 7.188 |
| Change At Month 48 | 2.02 ± 4.759 | 0.20 ± 5.170 |
ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at EOS (up to Month 53) and reported in this outcome measure.
| mcg/dL | BOS-BOS | PBO-BOS |
|---|---|---|
| Baseline | 10.49 ± 5.508 | 13.15 ± 7.188 |
| Change at EOS (Up to Month 53) | 0.96 ± 5.362 | 1.06 ± 6.138 |
Clinical laboratory parameters included hematology, chemistry, urinalysis; urine pregnancy test. Number of participants with potential clinically significant changes in laboratory parameters which were deemed clinically meaningful by the investigator were reported.
| Participants | BOS-BOS | PBO-BOS |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | 0 | 0 |
Collected over From start of study drug administration up to EOS (Up to Month 53). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BOS-BOS | 2/121 (1.7%) | 11/121 (9.1%) | 90/121 (74.4%) |
| PBO-BOS | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Event | BOS-BOS | PBO-BOS |
|---|---|---|
| Cardiogenic shockCardiac disorders | 1/121 | 0/10 |
| Myocardial infarctionCardiac disorders | 1/121 | 0/10 |
| Oesophageal perforationGastrointestinal disorders | 1/121 | 0/10 |
| Anaphylactic reactionImmune system disorders | 1/121 | 0/10 |
| AppendicitisInfections and infestations | 1/121 | 0/10 |
| OverdoseInjury, poisoning and procedural complications | 1/121 | 0/10 |
| Spinal compression fractureInjury, poisoning and procedural complications | 1/121 | 0/10 |
| ObesityMetabolism and nutrition disorders | 1/121 | 0/10 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/121 | 0/10 |
| Petit mal epilepsyNervous system disorders | 1/121 | 0/10 |
| Event | BOS-BOS | PBO-BOS |
|---|---|---|
| ACTH stimulation test abnormalInvestigations | 14/121 | 0/10 |
| Mitral valve incompetenceCardiac disorders | 0/121 | 1/10 |
| Tricuspid valve incompetenceCardiac disorders | 0/121 | 1/10 |
| NauseaGastrointestinal disorders | 4/121 | 1/10 |
| Oesophageal food impactionGastrointestinal disorders | 5/121 | 1/10 |
| Oesophageal stenosisGastrointestinal disorders | 2/121 | 1/10 |
| FatigueGeneral disorders | 1/121 | 1/10 |
| Drug hypersensitivityImmune system disorders | 0/121 | 1/10 |
| Seasonal allergyImmune system disorders | 0/121 | 1/10 |
| BronchitisInfections and infestations | 1/121 | 1/10 |
The safety analysis set (SAS) consisted of all participants who received at least 1 dose of BOS.
| Age, Continuous(years) | BOS-BOS | PBO-BOS | Total |
|---|---|---|---|
| Mean | 33.9 ± 12.65 | 40.2 ± 9.97 | 34.4 ± 12.55 |
| Age, Customized(Participants) | BOS-BOS | PBO-BOS | Total |
|---|---|---|---|
| Less than 18 years | 22 | 0 | 22 |
| 18 or more years | 99 | 10 | 109 |
| Sex: Female, Male(Participants) | BOS-BOS | PBO-BOS | Total |
|---|---|---|---|
| Female | 47 | 2 | 49 |
| Male | 74 | 8 | 82 |
| Ethnicity (NIH/OMB)(Participants) | BOS-BOS | PBO-BOS | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 3 |
| Not Hispanic or Latino | 117 | 10 | 127 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | BOS-BOS | PBO-BOS | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 4 | 0 | 4 |
| White | 109 | 10 | 119 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 0 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.
Ran from Oct 2017 to primary completion in Apr 2022, 54 months.
Results were first posted in Dec 2022, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide